Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma

Protocol No
NRG-HN014
Staff Member
Musaddiq Awan
Phase
III
Summary

This study is being done to answer the following question: Does giving immunotherapy before and after (in some cases) surgery extend the length of time without your cancer returning compared to the usual approach?
Objective
Trial of neoadjuvant immunotherapy vs. SOC for resectable cutaneous squamous cell carcinoma
Status
OPEN TO ACCRUAL
Categories
Cancer, Skin Cancers, Larynx, Head and Neck Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT06568172